In humans, several monoclonal antibodies that bind NGF (including tanezumab, fulranumab, and fasinumab) have been used in clinical studies in a range of chronic pain conditions such as osteoarthritis [for a comprehensive review, see (221)]. The gene discussed is NGF; the disease is osteoarthritis.